Macrogenics Inc (MGNX) 35.36 $MGNX
MacroGenics (MGNX) Downgraded From Hold to Sell
at The Street - Thu Mar 05, 11:40AM CST
MacroGenics (MGNX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+.
MGNX: 35.36 (-0.22)
MacroGenics' (MGNX) CEO Scott Koenig on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 8:18PM CST
MGNX: 35.36 (-0.22)
MacroGenics misses by $0.33, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 3:11PM CST
MGNX: 35.36 (-0.22)
MacroGenics (MGNX) Catches Eye: Stock Gains 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 8:11AM CST
MacroGenics, Inc. (MGNX) was a big mover last session, as the company saw its shares rise over 7% on the day.
MGNX: 35.36 (-0.22), PAHC: 35.01 (+0.10)
Zimmer (ZMH) Q4 Earnings Beat, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 10:13AM CST
Zimmer Holdings (ZMH) reported fourth-quarter 2014 adjusted earnings per share (EPS) of $1.71, up 3% year over year.
MGNX: 35.36 (-0.22), ZMH: 116.35 (-2.83), CSII: 36.10 (-1.36), OSUR: 7.17 (+0.06)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 35.36 (-0.22), JNJ: 100.11 (-2.41), UTHR: 160.65 (-0.71), MRK: 56.84 (-1.14), NNVC: 2.72 (-0.10), GSK: 46.73 (-0.87), SIGA: 2.40 (+0.04)
Medtronic Starts Cyro-FIRST Trial for AF Patients, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 1:40PM CST
Management at Medtronic (MDT) expects the AF patient population to expand exponentially over the next generation. Consequently, the cryoballoon ablation therapy should be able to garner high demand.
MGNX: 35.36 (-0.22), ICUI: 86.15 (-2.85), MDT: 76.48 (-2.02), CNAT: 6.05 (-0.54)
Surging Earnings Estimates Signal Good News for MacroGenics (MGNX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 7:42AM CST
The positive earnings estimate revisions suggest that analysts are becoming more optimistic on MacroGenics' (MGNX) earnings for the coming quarter and year
MGNX: 35.36 (-0.22)
Will MacroGenics (MGNX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 7:02AM CST
Will MacroGenics (MGNX) Continue to Surge Higher?
MGNX: 35.36 (-0.22)
Commit To Buy MacroGenics At $30, Earn 23.9% Annualized Using Options
at The Street - Tue Dec 30, 12:56PM CST
Investors eyeing a purchase of MacroGenics, Inc stock, but tentative about paying the going market price of $33.74/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
MGNX: 35.36 (-0.22)
Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Dec 26, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
MGNX: 35.36 (-0.22), CYTK: 7.80 (-0.11), JNJ: 100.11 (-2.41), ESRX: 82.27 (-2.01), ALNY: 107.67 (-3.89), GILD: 101.81 (-1.61), ACHN: 11.39 (+0.40), ABBV: 55.64 (-1.22), BMY: 65.12 (-0.93), ANIK: 39.63 (-0.33)
3D Systems Climbs Despite Setback
at The Street - Fri Dec 26, 1:00PM CST
Gulf Coast Ultra Deep Royalty Trust (NASDAQ:GULTU), MacroGenics Inc (NASDAQ:MGNX) and 3D Systems Corporation (NYSE
DD) are making notable gains this Friday. Posting losses today are Bio Blast Pharm...
MGNX: 35.36 (-0.22), DDD: 28.50 (-0.51), TAS: 0.54 (-0.03), ORPN: 7.03 (-0.35), GULTU: 0.96 (unch)
MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:00PM CST
MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development and commercialization of MGD011.
MGNX: 35.36 (-0.22), JNJ: 100.11 (-2.41), MDCO: 28.78 (-0.86), BMY: 65.12 (-0.93), FPRX: 24.55 (-1.09)
MacroGenics investors take some money off the table
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:12AM CST
MGNX: 35.36 (-0.22)
Equities Lead Investor Sentiments: Coverage Initiated on AMETEK, FedEx, MacroGenics, Walgreens and Apple
PR Newswire - Tue Dec 23, 8:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including AMETEK (NYSE: AME), FedEx (NYSE: FDX), MacroGenics (NASDAQ: MGNX), Walgreens (NYSE: WAG), and Apple (NASDAQ: AAPL). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
MGNX: 35.36 (-0.22), FDX: 173.19 (-1.63), AME: 52.02 (-0.90), AAPL: 126.60 (+0.19), WAG: 76.05 (-0.49)
MacroGenics, J&J make deal
at Investor's Business Daily - Mon Dec 22, 5:30PM CST
Biotech MacroGenics (MGNX) inked a licensing deal worth as much as $700 mil with Janssen Biotech, a Johnson & Johnson (JNJ) unit, which agreed to pay $50 mil upfront for rights to MGD011, an antibody that targets 2 biomarkers associated with...
MGNX: 35.36 (-0.22), JNJ: 100.11 (-2.41)
MacroGenics Partners With J&J; Stock Jumps
at Investor's Business Daily - Mon Dec 22, 11:33AM CST
Biotech MacroGenics (MGNX) cut a licensing deal worth as much as $700 million with Johnson & Johnson's drug-development arm Monday, sending its stock up 11% to a 10-month high above 38 on the stock market today. Johnson & Johnson's (JNJ) unit Janssen...
MGNX: 35.36 (-0.22), JNJ: 100.11 (-2.41)
MacroGenics teams up with Janssen in blood cancer
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:08AM CST
MGNX: 35.36 (-0.22), JNJ: 100.11 (-2.41)
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies
GlobeNewswire - Mon Dec 22, 5:00AM CST
-- MacroGenics licenses MGD011 (CD19 x CD3 DART(R)) to Janssen
MGNX: 35.36 (-0.22), JNJ: 100.11 (-2.41)
Is Boston Scientific (BSX) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:50PM CST
On Dec 16, 2014, Zacks Investment Research upgraded Boston Scientific Corporation (BSX) to a Zacks Rank #2 (Buy).
MGNX: 35.36 (-0.22), BSX: 16.56 (-0.41), ABAX: 62.39 (+0.24), HSP: 87.90 (+0.05)
MacroGenics (MGNX) Downgraded From Hold to Sell
at The Street - Thu Mar 05, 11:40AM CST
MacroGenics (MGNX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+.
MGNX: 35.36 (-0.22)
MacroGenics' (MGNX) CEO Scott Koenig on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 8:18PM CST
MGNX: 35.36 (-0.22)
MacroGenics misses by $0.33, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 3:11PM CST
MGNX: 35.36 (-0.22)
MacroGenics (MGNX) Catches Eye: Stock Gains 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 8:11AM CST
MacroGenics, Inc. (MGNX) was a big mover last session, as the company saw its shares rise over 7% on the day.
MGNX: 35.36 (-0.22), PAHC: 35.01 (+0.10)
Zimmer (ZMH) Q4 Earnings Beat, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 10:13AM CST
Zimmer Holdings (ZMH) reported fourth-quarter 2014 adjusted earnings per share (EPS) of $1.71, up 3% year over year.
MGNX: 35.36 (-0.22), ZMH: 116.35 (-2.83), CSII: 36.10 (-1.36), OSUR: 7.17 (+0.06)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 35.36 (-0.22), JNJ: 100.11 (-2.41), UTHR: 160.65 (-0.71), MRK: 56.84 (-1.14), NNVC: 2.72 (-0.10), GSK: 46.73 (-0.87), SIGA: 2.40 (+0.04)
Medtronic Starts Cyro-FIRST Trial for AF Patients, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 1:40PM CST
Management at Medtronic (MDT) expects the AF patient population to expand exponentially over the next generation. Consequently, the cryoballoon ablation therapy should be able to garner high demand.
MGNX: 35.36 (-0.22), ICUI: 86.15 (-2.85), MDT: 76.48 (-2.02), CNAT: 6.05 (-0.54)
Surging Earnings Estimates Signal Good News for MacroGenics (MGNX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 7:42AM CST
The positive earnings estimate revisions suggest that analysts are becoming more optimistic on MacroGenics' (MGNX) earnings for the coming quarter and year
MGNX: 35.36 (-0.22)
Will MacroGenics (MGNX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 7:02AM CST
Will MacroGenics (MGNX) Continue to Surge Higher?
MGNX: 35.36 (-0.22)
Commit To Buy MacroGenics At $30, Earn 23.9% Annualized Using Options
at The Street - Tue Dec 30, 12:56PM CST
Investors eyeing a purchase of MacroGenics, Inc stock, but tentative about paying the going market price of $33.74/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
MGNX: 35.36 (-0.22)
Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Dec 26, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
MGNX: 35.36 (-0.22), CYTK: 7.80 (-0.11), JNJ: 100.11 (-2.41), ESRX: 82.27 (-2.01), ALNY: 107.67 (-3.89), GILD: 101.81 (-1.61), ACHN: 11.39 (+0.40), ABBV: 55.64 (-1.22), BMY: 65.12 (-0.93), ANIK: 39.63 (-0.33)
3D Systems Climbs Despite Setback
at The Street - Fri Dec 26, 1:00PM CST
Gulf Coast Ultra Deep Royalty Trust (NASDAQ:GULTU), MacroGenics Inc (NASDAQ:MGNX) and 3D Systems Corporation (NYSE
DD) are making notable gains this Friday. Posting losses today are Bio Blast Pharm... MGNX: 35.36 (-0.22), DDD: 28.50 (-0.51), TAS: 0.54 (-0.03), ORPN: 7.03 (-0.35), GULTU: 0.96 (unch)
MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:00PM CST
MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development and commercialization of MGD011.
MGNX: 35.36 (-0.22), JNJ: 100.11 (-2.41), MDCO: 28.78 (-0.86), BMY: 65.12 (-0.93), FPRX: 24.55 (-1.09)
MacroGenics investors take some money off the table
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:12AM CST
MGNX: 35.36 (-0.22)
Equities Lead Investor Sentiments: Coverage Initiated on AMETEK, FedEx, MacroGenics, Walgreens and Apple
PR Newswire - Tue Dec 23, 8:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including AMETEK (NYSE: AME), FedEx (NYSE: FDX), MacroGenics (NASDAQ: MGNX), Walgreens (NYSE: WAG), and Apple (NASDAQ: AAPL). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
MGNX: 35.36 (-0.22), FDX: 173.19 (-1.63), AME: 52.02 (-0.90), AAPL: 126.60 (+0.19), WAG: 76.05 (-0.49)
MacroGenics, J&J make deal
at Investor's Business Daily - Mon Dec 22, 5:30PM CST
Biotech MacroGenics (MGNX) inked a licensing deal worth as much as $700 mil with Janssen Biotech, a Johnson & Johnson (JNJ) unit, which agreed to pay $50 mil upfront for rights to MGD011, an antibody that targets 2 biomarkers associated with...
MGNX: 35.36 (-0.22), JNJ: 100.11 (-2.41)
MacroGenics Partners With J&J; Stock Jumps
at Investor's Business Daily - Mon Dec 22, 11:33AM CST
Biotech MacroGenics (MGNX) cut a licensing deal worth as much as $700 million with Johnson & Johnson's drug-development arm Monday, sending its stock up 11% to a 10-month high above 38 on the stock market today. Johnson & Johnson's (JNJ) unit Janssen...
MGNX: 35.36 (-0.22), JNJ: 100.11 (-2.41)
MacroGenics teams up with Janssen in blood cancer
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:08AM CST
MGNX: 35.36 (-0.22), JNJ: 100.11 (-2.41)
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies
GlobeNewswire - Mon Dec 22, 5:00AM CST
-- MacroGenics licenses MGD011 (CD19 x CD3 DART(R)) to Janssen
MGNX: 35.36 (-0.22), JNJ: 100.11 (-2.41)
Is Boston Scientific (BSX) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:50PM CST
On Dec 16, 2014, Zacks Investment Research upgraded Boston Scientific Corporation (BSX) to a Zacks Rank #2 (Buy).
MGNX: 35.36 (-0.22), BSX: 16.56 (-0.41), ABAX: 62.39 (+0.24), HSP: 87.90 (+0.05)
